What's the Half-Life of Wolverine Stack? (Clearance Guide)

The half-life of the Wolverine Stack isn't a single number. It's a clearance timeline defined by three distinct peptides with radically different elimination rates. CJC-1295 with DAC (Drug Affinity Complex) has a half-life of approximately 6–8 days, making it the longest-persisting component by far. Ipamorelin clears plasma within 2 hours after subcutaneous injection. GHRP-6 follows a similar trajectory, exiting the bloodstream in 3–4 hours. What this means in practice: the growth hormone pulse from Ipamorelin and GHRP-6 hits fast and fades within hours, while CJC-1295 DAC continues amplifying baseline GH secretion for nearly a week after a single dose. That's not a bug. It's the design.

We've worked with hundreds of researchers exploring peptide protocols, and the confusion around Wolverine Stack timing is consistent. The stack works because of the mismatch in clearance rates. Not despite it.

What's the half-life of the Wolverine Stack?

The Wolverine Stack has three distinct half-lives: CJC-1295 DAC persists for 6–8 days with sustained GH-releasing activity, while Ipamorelin and GHRP-6 clear plasma within 2–4 hours post-injection. This creates a dual-phase effect. An immediate GH pulse from the short-acting peptides followed by continuous baseline elevation from CJC-1295 DAC across the entire week.

Direct Answer: Why the Half-Life Mismatch Matters

Most people assume peptide stacks work synchronously. That all compounds should have similar clearance times. That's the opposite of how the Wolverine Stack functions. The extended half-life of CJC-1295 DAC (6–8 days) creates a sustained amplification platform. When you inject Ipamorelin and GHRP-6 on top of that elevated baseline, the resulting GH pulse is significantly higher than either peptide would produce alone. The short-acting peptides trigger the pulse; CJC-1295 DAC amplifies the signal. This article covers the exact elimination timeline for each peptide, what drives the half-life differences, and how clearance timing affects dosing frequency and measurable outcomes in research settings.

How Each Peptide in the Wolverine Stack Clears the Body

CJC-1295 with DAC is a modified form of growth hormone-releasing hormone (GHRH) engineered to resist enzymatic degradation. The DAC molecule. A maleimide derivative that binds to serum albumin. Extends the peptide's half-life from under 30 minutes (for unmodified CJC-1295) to 6–8 days. Once injected subcutaneously, CJC-1295 DAC binds to albumin in the bloodstream, creating a reservoir that slowly releases active peptide over days. Plasma GH-releasing activity remains elevated for up to 13 days after a single 2mg dose, though peak effects occur within the first 72 hours.

Ipamorelin is a growth hormone secretagogue that binds to the ghrelin receptor (GHS-R1a) without triggering prolactin or cortisol elevation. A selectivity advantage over earlier GHRPs. Its half-life is approximately 2 hours after subcutaneous administration. Plasma levels peak 20–30 minutes post-injection, trigger a GH pulse within 45 minutes, and return to baseline within 4 hours. The short clearance window is intentional: Ipamorelin mimics natural pulsatile GH release rather than creating sustained supraphysiological levels.

GHRP-6 (Growth Hormone Releasing Peptide-6) also targets GHS-R1a but with broader downstream effects. It stimulates appetite via ghrelin pathways and increases IGF-1 more aggressively than Ipamorelin. Its half-life is 3–4 hours, slightly longer than Ipamorelin but still within the rapid-clearance category. GHRP-6 reaches peak plasma concentration 30–60 minutes after injection and triggers maximal GH secretion 60–90 minutes post-dose. By hour five, circulating GHRP-6 is functionally undetectable.

Why CJC-1295 DAC Has a 6–8 Day Half-Life

The DAC modification fundamentally changes how the body processes CJC-1295. Unmodified GHRH analogs are cleaved by dipeptidyl peptidase-4 (DPP-4) and neprilysin within minutes of entering circulation. The DAC molecule prevents enzymatic access to the cleavage sites by sterically shielding the peptide backbone while bound to albumin. Albumin itself has a half-life of approximately 19 days in human plasma, which means the CJC-1295–albumin complex persists far longer than the free peptide ever could.

This extended circulation doesn't mean CJC-1295 DAC is continuously active at the same intensity. GH-releasing activity follows a dose-response curve: peak pituitary stimulation occurs in the first 48–72 hours, then gradually declines as circulating peptide concentration drops below the receptor activation threshold. By day 7–8, residual CJC-1295 DAC remains detectable in serum, but its biological effect. Measured as serum GH elevation. Has returned to near-baseline. The half-life describes plasma clearance, not receptor occupancy or functional duration.

Our team has found that researchers often confuse half-life with duration of action. A 6-day half-life means half the injected dose remains after six days. Not that the peptide continues driving maximal GH secretion for six days. By day 4–5, most of the functional GH elevation has already occurred.

Wolverine Stack Comparison: Half-Life vs Functional Duration

CJC-1295 DAC's extended half-life creates a baseline GH elevation that lasts across multiple dosing cycles of the short-acting peptides. Ipamorelin and GHRP-6 produce acute pulses that mimic natural GH secretion patterns, then clear completely before the next dose. The combination. Long-acting GHRH analog + short-acting GH secretagogues. Replicates physiological pulsatility on top of a slightly elevated baseline, which research suggests may optimize receptor sensitivity and downstream IGF-1 production more effectively than either approach alone.

Key Takeaways

• CJC-1295 with DAC has a half-life of 6–8 days due to albumin binding, making it the longest-persisting peptide in the Wolverine Stack by a factor of 30–40× compared to Ipamorelin and GHRP-6.
• Ipamorelin clears plasma within 2 hours and produces a single GH pulse lasting 2–3 hours, then returns to baseline. This rapid clearance is what allows twice-daily dosing without receptor desensitization.
• GHRP-6 has a slightly longer half-life (3–4 hours) than Ipamorelin but follows the same rapid-clearance profile, with functional GH elevation gone within 5–6 hours post-injection.
• The Wolverine Stack's effectiveness depends on the clearance mismatch. CJC-1295 DAC amplifies baseline GH secretion while Ipamorelin and GHRP-6 create acute pulses on top of that elevated baseline.
• Researchers using Real Peptides' Wolverine Stack formulations can rely on small-batch synthesis with exact amino-acid sequencing to ensure consistent clearance profiles across research cycles.

What If: Wolverine Stack Half-Life Scenarios

What If You Miss a CJC-1295 DAC Dose?

Administer the missed dose as soon as you remember if fewer than 4 days have passed since the scheduled injection. CJC-1295 DAC's 6–8 day half-life means residual peptide is still circulating and active even 72–96 hours after the intended dose. If more than 5 days have passed, skip the missed dose entirely and resume on your next scheduled date. Doubling up creates unnecessarily high plasma levels without proportional benefit. The extended half-life provides a built-in buffer that shorter peptides don't offer.

What If You Inject Ipamorelin Without CJC-1295 DAC?

You'll get a normal GH pulse. Ipamorelin works independently and doesn't require CJC-1295 to trigger GH release. The difference is magnitude: without the baseline GHRH stimulation from CJC-1295 DAC, the Ipamorelin-induced pulse will be smaller. Research comparing standalone Ipamorelin to combination protocols shows 30–40% higher peak GH levels when layered on top of a GHRH analog. If CJC-1295 DAC is unavailable or contraindicated, Ipamorelin alone remains a viable GH secretagogue. It's just less synergistic.

What If You Want Faster Clearance Than 6–8 Days?

Switch to CJC-1295 without DAC (also called Modified GRF 1-29). The unmodified version has a half-life under 30 minutes and clears completely within 2–3 hours, making it functionally identical to Ipamorelin in clearance speed. This eliminates the extended baseline elevation but also removes the amplification effect that makes the Wolverine Stack distinct. Faster clearance is appropriate for research models requiring tighter temporal control over GH pulses, but it requires more frequent dosing. Typically 2–3× daily rather than weekly for the DAC version.

The Unvarnished Truth About Wolverine Stack Clearance

Here's the honest answer: the 6–8 day half-life of CJC-1295 DAC is both the stack's biggest strength and its most misunderstood feature. Researchers expect peptides to clear quickly. Most do. When they see "8-day half-life," they assume continuous high-intensity GH stimulation for a full week. That's not how it works. The biological effect peaks in the first 72 hours and tapers significantly by day 5, even though measurable peptide remains in plasma. You're not getting eight full days of maximal GH elevation. You're getting a strong 3-day window with a gradual decline across days 4–7.

The persistence matters less for immediate outcomes and more for protocol convenience. A once-weekly CJC-1295 DAC injection maintains sufficient baseline GHRH activity to amplify every Ipamorelin and GHRP-6 pulse across the week. Without that long tail, you'd need to dose a GHRH analog 2–3× daily to achieve the same synergy. The half-life isn't about maximizing GH. It's about simplifying the dosing schedule without sacrificing the amplification effect.

How Reconstitution and Storage Affect Half-Life Stability

The half-life numbers assume properly reconstituted and stored peptides. CJC-1295 DAC, Ipamorelin, and GHRP-6 are all supplied as lyophilized powder and must be reconstituted with bacteriostatic water before use. Once mixed, the peptides remain stable at 2–8°C (refrigerated) for 28 days. After that window, degradation accelerates regardless of the peptide's native half-life in vivo. Temperature excursions above 8°C cause irreversible structural changes to the peptide backbone, which shortens the functional half-life unpredictably.

The DAC modification in CJC-1295 makes it slightly more stable in solution than unmodified GHRH analogs, but it's not immune to heat degradation. A vial of CJC-1295 DAC left at room temperature for 48 hours may still look clear and normal, but the albumin-binding affinity can be compromised. Meaning the in vivo half-life drops from 6–8 days to something closer to hours. There's no home test for this. If you're uncertain whether a reconstituted peptide was stored correctly, discard it and reconstitute fresh. The cost of replacing a $40 vial is trivial compared to an entire research cycle with inactive compounds.

Researchers working with Real Peptides benefit from small-batch synthesis that guarantees exact sequencing before lyophilization. The peptides start with full structural integrity, which maximizes the clearance consistency you'd expect from published half-life data.

The Wolverine Stack's clearance profile isn't a flaw. It's a feature. The long half-life of CJC-1295 DAC simplifies weekly dosing while the short half-lives of Ipamorelin and GHRP-6 preserve natural pulsatility. Understanding the elimination timeline for each peptide allows researchers to design protocols that maximize synergy without creating unnecessarily sustained supraphysiological GH levels. If you're evaluating peptide stacks for research applications, half-life compatibility matters as much as receptor mechanism.